Eritel CH 40 Trio Tablet is a combination antihypertensive medication containing Telmisartan 40 mg, Amlodipine 5 mg, and Chlorthalidone 12.5 mg. This formulation is indicated for the management of hypertension, providing effective blood pressure control through complementary mechanisms of action. Telmisartan, an angiotensin II receptor blocker (ARB), inhibits the vasoconstrictive effects of angiotensin II, thereby reducing peripheral vascular resistance. Amlodipine, a calcium channel blocker, promotes vasodilation by inhibiting calcium ion influx into vascular smooth muscle cells, further lowering blood pressure. Chlorthalidone, a thiazide-like diuretic, facilitates sodium and water excretion, reducing plasma volume and contributing to antihypertensive effects. The combination enhances therapeutic efficacy and may improve patient adherence by reducing pill burden. Eritel CH 40 Trio Tablet is typically prescribed when monotherapy or dual therapy does not achieve adequate blood pressure control. It is essential to monitor renal function, electrolyte levels, and blood pressure regularly during treatment to detect potential adverse effects such as hypotension, electrolyte imbalances, or renal impairment. Contraindications include hypersensitivity to any component, severe renal or hepatic impairment, and pregnancy. Patients should be advised to maintain regular follow-up and adhere to lifestyle modifications alongside pharmacotherapy for optimal hypertension management.